C&EN’s Year in Pharma 2022: Oncology, Big Pharma top out US FDA’s 2022 approvals
Gene therapies, novel psoriasis drugs, and a Botox rival are among notable green-lit products
Gene therapies, novel psoriasis drugs, and a Botox rival are among notable green-lit products